Clauzel A M, Calvayrac P, Michel F B
Poumon Coeur. 1980 Sep-Oct;36(5):295-302.
The present paper studies in asthmatic patients the variations of the plasmatic levels of cAMP and cGMP as control of an eventual adrenergic beta receptors trouble. The first part includes the study of relations of the plasmatic level of nucleotides with the parameters: age, sex, time of sampling in a population of normal subjects (n = 91) and asthmatic patients (n = 203). There is a significant correlation between the age and the level of plasmatic cAMP in normal subject (r = 0.63) as well as in asthmatic patients (r = 0.73). Age for age, there is no difference between the plasmatic levels of controls and the asthmatic patients. The cGMP level is stable, identical in asthmatic (18 p mu +/- 1.74/ml) and in normal subjects (16.84 p mu +/- 2.77 p mu/ml). No nycthemeral rhythm has been revealed. The second part examines the variations of plasmatic levels of cyclic nucleotids during pharmacodynamic assay: methylcholine, beta blocking drugs, spray and subcutaneous sympathomimetics, corticotherapy. No variation of cAMP and cGMP was shown after inhalation of methylcholine or injection of beta blocking drugs able to induce or to reveal a bronchospasm. On the other hand the sympathomimetic drugs, whatever mean of introduction, bring a significant increase of the average level of cAMP going from 40 p mu/ml +/- 5.09 to 101 p mu/ml +/- 4.67 in healthy subject and of 49.42 p mu/ml +/- 10.10 to 74.38 p mu/ml +/- 13.7 in asthmatic patients. The difference in variation amplitude between asthmatic and control subjects is significant, the asthmatic patients responding less to a beta adrenergic stimulation. The plasmatic cGMP remains unchanged during the assay. Corticotherapy does not modify the initial level of cAMP but restores the response to a beta adrenergic stimulation. Inhalation of cAMP dibutyryl restores the bronchial permeability. The study of the variations of plasmatic levels of cAMP reveals a hyposensitivity of the whole of beta adrenergic receptors in asthmatic patients. The former varies in time and can be normalized either spontaneously or by corticotherapy.
本文研究哮喘患者血浆中环磷酸腺苷（cAMP）和环磷酸鸟苷（cGMP）水平的变化，以控制可能存在的肾上腺素能β受体问题。第一部分包括研究正常受试者（n = 91）和哮喘患者（n = 203）群体中核苷酸血浆水平与年龄、性别、采样时间等参数的关系。在正常受试者（r = 0.63）和哮喘患者（r = 0.73）中，年龄与血浆cAMP水平之间存在显著相关性。同一年龄段，对照组和哮喘患者的血浆水平无差异。cGMP水平稳定，哮喘患者（18皮摩尔±1.74/毫升）和正常受试者（16.84皮摩尔±2.77皮摩尔/毫升）相同。未发现昼夜节律。第二部分研究药效学检测过程中循环核苷酸血浆水平的变化：乙酰甲胆碱、β受体阻滞剂、喷雾和皮下注射拟交感神经药、皮质激素疗法。吸入乙酰甲胆碱或注射能诱发或揭示支气管痉挛的β受体阻滞剂后，cAMP和cGMP未显示变化。另一方面，无论采用何种给药方式，拟交感神经药都会使健康受试者的cAMP平均水平显著升高，从40皮摩尔/毫升±5.09升至101皮摩尔/毫升±4.67，哮喘患者从49.42皮摩尔/毫升±10.10升至74.38皮摩尔/毫升±13.7。哮喘患者和对照受试者的变化幅度差异显著，哮喘患者对β肾上腺素能刺激的反应较小。检测过程中血浆cGMP保持不变。皮质激素疗法不会改变cAMP的初始水平，但能恢复对β肾上腺素能刺激的反应。吸入二丁酰cAMP可恢复支气管通透性。对血浆cAMP水平变化的研究揭示了哮喘患者整体β肾上腺素能受体的低敏性。前者随时间变化，可自发或通过皮质激素疗法恢复正常。
